Multicenter clinical evaluation of the novel Alere™ i Influenza A&B isothermal nucleic acid amplification test  by Bell, Jeremiah et al.
M
i
J
W
a
b
c
d
e
f
g
h
a
A
R
R
A
K
I
R
A
P
N
1
i
e
[
y
p
K
h
1Journal of Clinical Virology 61 (2014) 81–86
Contents lists available at ScienceDirect
Journal of Clinical Virology
journa l homepage: www.e lsev ier .com/ locate / j cv
ulticenter clinical evaluation of the novel AlereTM i Inﬂuenza A&B
sothermal nucleic acid ampliﬁcation test
eremiah Bell a,b, Aleta Bonnerc, Daniel M. Cohend, Robert Birkhahne, Ram Yogevf,
ayne Trinerg, Jason Coheng, Elizabeth Palavecinoh, Rangaraj Selvarangana,b,∗
Children’s Mercy Hospitals and Clinics, Kansas City, MO, United States
University of Missouri Kansas City School of Medicine, Kansas City, MO, United States
Veritas, P.A., Belton, TX, United States
Nationwide Children’s and the Ohio State University, Columbus, OH, United States
New York Methodist Hospital, Brooklyn, NY, United States
Ann & Robert Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, United States
Albany Medical College, Albany, NY, United States
Wake Forest University Baptist Medical Center, Winston-Salem, NC, United States
r t i c l e i n f o
rticle history:
eceived 21 March 2014
eceived in revised form 29 May 2014
ccepted 1 June 2014
eywords:
nﬂuenza
ADT
lereTM i Inﬂuenza
OC
ucleic acid ampliﬁcation
a b s t r a c t
Background: Rapid detection of inﬂuenza infection is important for patient management and timely anti-
viral therapy. Rapid antigen detection tests for inﬂuenza have inferior sensitivity when compared to
nucleic acid-based ampliﬁcation tests. An isothermal nucleic acid ampliﬁcation test that offers the poten-
tial for rapidmolecular testing at the clinical point-of-carewith simple equipment can improve inﬂuenza
detection rates.
Objectives: To evaluate the performance of AlereTM i Inﬂuenza A&B isothermal nucleic acid ampliﬁcation
test to detect inﬂuenza A and B in comparison to viral cell culture as reference method.
Study design:A prospective,multicenter, clinical study to evaluate the clinical performance of the AlereTM
i InﬂuenzaA&Bassay in apoint-of-care settingusingprospectively enrolled specimens fromboth children
and adults was conducted in seven sites.
Results: In comparison with viral cell culture, the overall sensitivity and speciﬁcity of the AlereTM i
Inﬂuenza A&B assay was 97.8% and 85.6% for the detection of inﬂuenza A, and 91.8% and 96.3% for the
detection of inﬂuenza B, respectively. Following resolution of discrepant results by real-time RT-PCR the
TMsensitivity and speciﬁcity of the Alere i Inﬂuenza A&B assay improved to 99.3% and 98.1% for inﬂuenza
A, and 97.6% and 100% for inﬂuenza B, respectively.
Conclusions: The AlereTM i Inﬂuenza A&B isothermal nucleic acid ampliﬁcation test is an ideal point-of-
care test for inﬂuenza detection in children and adults due to its high sensitivity and speciﬁcity and ability
to generate results within 15min from specimen receipt.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND. Background
Inﬂuenza viruses cause respiratory illnesses that manifest clin-
cally with common symptoms of fever, headache, body aches,
xtreme tiredness, nausea, stuffy nose or rhinitis, and dry cough
1,2]. Persons at increased risk for severe disease or death include
oung children (especially those less than two years of age),
regnant women, older adults, and persons of any age with
∗ Corresponding author at: Microbiology Laboratory, Children’s Mercy Hospital,
ansas City, MO 64108, United States. Tel.: +1 816 234 3031; fax: +1 816 802 1492.
E-mail address: rselvarangan@cmh.edu (R. Selvarangan).
ttp://dx.doi.org/10.1016/j.jcv.2014.06.001
386-6532/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
compromised respiratory, cardiac, or immune systems [3–7].
Respiratory infections continue to have yearly major economic
impact and antiviral treatments need to be given within the ﬁrst
three to four days to have any signiﬁcant effect [4,6,8–13].
Several methods exist for the detection of inﬂuenza virus infec-
tion in the laboratory, each with advantages and disadvantages.
Viral cell culture, direct ﬂuorescent antibody staining (DFA), and
real-time reverse transcriptionpolymerase chain reaction (RT-PCR)
are all commonly used in hospital-based clinical settings where
larger laboratories are available [3,14–19]. Rapid antigen-detection
tests (RADT) for inﬂuenza are generally at the front line of diag-
nosis especially at point-of-care (POC) settings such as outpatient
clinics and emergency departments. Though not as sensitive as the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ther methods mentioned above, these rapid antigen tests provide
quick turnaround time from sample collection to result that allow
etter patient management in POC sites [20]. Although RT-PCR is
ecoming increasingly accepted as a gold standard over viral cell
ulture for detection of inﬂuenza viruses, it is technically demand-
ng, laborious, andexpensive [21]. Additionally,whileRT-PCRoffers
relatively quickmethod from sample collection to result, it is still
ot helpful in managing the increased patient volumes often seenw chart.
in busy emergency departments and larger clinical practices. The
decreased sensitivity of RADT assays has long been an acceptable
tradeoff for the acquisition of rapid results even at some hospi-
tals with the potential for performing more complex detection
methods.
Improved molecular detection techniques that can provide
results more rapidly as to signiﬁcantly impact patient care have
been used to diagnose several infectious diseases. The isothermal
nical Virology 61 (2014) 81–86 83
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ucleic acid ampliﬁcation technique allows nucleic acid ampliﬁca-
ion in a very narrow temperature range, eliminating the need for
xpensive thermal cyclers and allowing for results to be obtained
uickly [21–25]. The AlereTM i Inﬂuenza A&B assay is a rapid and
utomated in vitro diagnostic test for the qualitative detection of
nﬂuenza A and B that uses isothermal nucleic acid ampliﬁcation
echnology to detect viral RNA from respiratory specimens. Results
re available within 15min from sample collection. Additionally,
he technology has been simpliﬁed and packaged in an easy to use
evice so that non-laboratorian POC personnel will be able to per-
orm it, representing an added beneﬁt by allowing the use of the
ssay at POC outpatient settings.
. Objective
The objective of this study is to evaluate the performance of
lereTM i Inﬂuenza A&B isothermal nucleic acid ampliﬁcation test
o detect inﬂuenza A and B in comparison to viral cell culture as
eference method.
. Study design
A ﬂow diagram of the overall study design is depicted in Fig. 1.
s deemednecessary for better understanding, details of individual
teps and components of the study are described further below.
.1. Subjects and specimens
Respiratory nasal swab specimens were prospectively collected
uring the 2012–2013 respiratory seasons at seven clinical sites
round the United States. Subjects were eligible to participate if
resented to participating clinical sitewith a fever (≥37.8 ◦C/100F),
R self-reported having had or were currently treating a fever
37.8 ◦C/100Fwithonsetwithin theprevious72h,AND at least one
dditional ﬂu-like symptom including, headache, extreme tired-
ess, dry cough, sore throat, runny or stuffy nose, or muscle aches.
ubjects were considered ineligible if they received a nasal vaccine
i.e., FluMist®) within the past ten (10) days, were taking at the
ime of enrollment or had taken an antiviralmedication (i.e., aman-
adine, rimantadine, Relenza® (zanamivir), Tamiﬂu® (oseltamivir
hosphate), and Flumadine®) for inﬂuenza within the previous 30
ays, or were enrolled in another study to evaluate a new drug.
From each subject, two respiratory specimens were collected
ith foam-tipped swabs from the external nares of the same nos-
ril, one for testing with R-mix shell vial viral culture and the other
or direct testing on the AlereTM i Inﬂuenza A&B assay. To avoid
otential bias in the sample collection and subsequent testing, the
rder of collection of swabs from each subject was randomized
uch that if the swab for viral culture was collected ﬁrst for one
ubject then the swab for AlereTM i Inﬂuenza A&B assay was col-
ected ﬁrst for the next subject. This alternating collection routine
as repeated for all subjects. Testing with the AlereTM i Inﬂuenza
&B assay was performed directly by the POC enrollers. Prior to
tudy initiation, each enroller that was to conduct testing received
nly basic, minimal instruction on operation of the investigational
evice from the sponsor-provided study protocol, quick reference
uide and instrument-guided graphics as described below. Each
nroller demonstrated proﬁciency by testing of a positive and/or
egative kit control swab prior to subject testing.
.2. AlereTM i Inﬂuenza A&B nucleic acid ampliﬁcation testingA schematic of the testing procedure is provided in Fig. 2 and
llustration of technology is provided in Fig. 3. Brieﬂy, the test base
s inserted into the appropriate color-coded receptacle, followedFig. 2. Overview of the AlereTM i Inﬂuenza A&B assay.
by placing the sample receiver into the corresponding color-coded
receptacle. The sample receiver and buffer inside are then heated
for 3min on-board the instrument. Following the heating step,
specimen is eluted from the swab directly into the sample receiver
by swirling the swab into the buffer contained in the sample
receiver. The transfer cartridge is then used to transfer sample to
the test base. Once this step has been conﬁrmed by the user, the
device door is closed, ampliﬁcation begins, and results are avail-
able within 10min. AlereTM i Inﬂuenza A&B contains an internal
control that has been designed to control for sample inhibition,
ampliﬁcation and assay reagent function. All instructions are pro-
vided by animated graphics on the instrument display to prompt
the user. For the study, positive and negative quality control swabs
were processed every day before testing of study specimens. Fresh
nasal swabs were tested within 2h following collection at room
temperature or up to 24h with refrigeration.
3.3. Respiratory viral culture
Viral culture was performed using Diagnositc Hybrids Rmix/R-
MixTooTM shell vials (Quidel, San Diego, CA) followed by detection
with either Light DiagnosticsTM SimulFluor® FluA/FluB reagent or
DiagnosticHybridsD3 UltraTM DFARespiratoryVirus Screening and
ID Kit according to each site’s standard protocol. Two shell vials
were inoculated and one stained with anti-inﬂuenza ﬂuorescent
antibody on day 2 and if negative the second vial was stained using
the same technique on day 5.
3.4. Discrepant analysis
ProdesseTM ProFlu+TM real-time RT-PCR was performed on
discordant specimens at the clinical laboratory of one of the partic-
ipating sites (Site 001A).
3.5. Specimen analysis
Results obtained with the AlereTM i Inﬂuenza A&B nucleic
acid ampliﬁcation test were compared to those obtained by the
viral shell vial culture (along with PCR discrepant analysis when
required) to determine the assay performance. The statistical anal-
yses included all specimens that yielded a valid test result for both
the AlereTM i Inﬂuenza A&B assay and the comparator viral cul-
turemethod. Reportable datawere summarized in two by two data
tables listing the number of specimens in each of the four (4) result
categories; true positive (TP), true negative (TN), false positive (FP)
and false negative (FN). Sensitivity, speciﬁcity, positive predictive
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Fig. 3. Schematic representation of AlereTM i Inﬂuenza A&B assay technology. As the reaction is initiated, a reverse transcription step generates a complimentary DNA strand
from viral RNA, which then serves as a template for genesis of double-stranded DNA. Both template strands are then cut by a nicking enzyme (A). DNA Polymerase then sits
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Tt nick sites and unravels template (B1). Polymerase elongates reaction products thr
he growing reaction product can be displaced by new primer (C2). The reaction pr
o be repeated for rapid ampliﬁcation of products (E).
alue (PPV) and negative predictive value (NPV) were determined.
onﬁdence intervals at 95% were calculated by the Wald method.
. Results
A total of 545 respiratory nasal swab specimens were collected;
65 children and 80 adults. Children ranged in age from 1month to
7 years old (mean=4 years; median=3 years; 231 females), and
dults ranged in age from 18 to 88 years (mean=36; median=31;
7 females). Of the 545 specimens enrolled into the study, two
pecimens yielded uninterpretable viral culture results due to cell
ulture contamination. With AlereTM i Inﬂuenza A&B testing, there
ere 11 specimens with invalid Inﬂuenza A results (invalid rate
% and 15 specimens with invalid Inﬂuenza B results (invalid rate
.8%) and one additional sample excluded due to both inﬂuenza
and B being detected. The overall performance of the AlereTM i
nﬂuenza A&B nucleic acid ampliﬁcation test in comparison with
iral cell culture is shown in Table 1. The assay demonstrated
xcellent sensitivity for detection of inﬂuenza A and inﬂuenza B,
7.8% and 91.8%, respectively, but lower speciﬁcity (85.6% and
6.3%, respectively). With initial analysis comparing it to viral cul-
ure, the speciﬁcity for detection of inﬂuenza A, as well as the
PV for both inﬂuenza A and inﬂuenza B was low due to samples
eing positive by the AlereTM i Inﬂuenza A&B assay but negative
y culture. Since the AlereTM i Inﬂuenza A&B assay is a molecu-
ar ampliﬁcation method, it has the potential to be more sensitive
han the shell vial viral culture method (used as the comparator),
nd may produce more FP results. Therefore, the FP samples were
lso tested by the ProdesseTM ProFlu+TM real-time RT-PCR assay.
mong the 62 FP inﬂuenza A tested (one sample was not avail-
ble), 55 were conﬁrmed as inﬂuenza A by ProFlu+TM assay and
even were considered true false positive. Among the 17 FP for
nﬂuenza B, 16 were conﬁrmed as TP by the ProFlu+TM assay. One
pecimen was positive for inﬂuenza B by AlereTM i Inﬂuenza A&B
ssay and ProFlu+TM assay while the culture detected inﬂuenza A.
his specimen was considered FP in the original analysis but sub-
equently removed from the composite analysis since results from
oth reference methods (culture and ProFlu assay) differed. The
FN inﬂuenza A was also negative with the ProFlu+TM and four
f six FN inﬂuenza B were also negative by the ProFlu+TM assay.
he resulting data (following the discrepant analysis) are shown in
able 2 and demonstrate substantial increased sensitivity for theut test duration (B2). Ampliﬁcation primers bind loosely to template (C1) such that
s from both directions (D) and nick-sites within the primers allow for the process
AlereTM i InﬂuenzaA&Bassay indetecting inﬂuenzaAand inﬂuenza
B at 99.3% and 97.6%, respectively. In addition, the speciﬁcities after
the ProFlu+TM assay, discrepant analysis were 98.1% and 100% for
inﬂuenza A and inﬂuenza B, respectively. The PPV and NPV for
detection of inﬂuenza A were 95.3% and 99.7%, and for inﬂuenza
B 100% and 99.5%, respectively.
Since both children (<18 years of age) and adults were enrolled
in the study, we analyzed the data separately for each group. Sen-
sitivity for detection of inﬂuenza A in children and adults was
99.2% and 100%, respectively, while the speciﬁcity was 98.4% and
96.5%, respectively. The sensitivity for detection of inﬂuenza B was
97.2% and 100%, and the speciﬁcity was 100% for both groups. Both
PPV and NPV for children and adults were also very good – 89.4%
and100%, respectively (Table 3).
5. Discussion
Viral cell culture and molecular techniques such as real-time
RT-PCR are considered the reference methods for detection of
inﬂuenza A and B. Generally, such techniques are only available
at hospital-based or reference laboratories due to the necessity
for skilled laboratory technicians and the high cost of equipments
and reagents. Unfortunately, viral culture results take days and
although results from some PCR-based assays can be obtained in
1–1.5h, practical turnaround time is longer. In order to obtain test-
ing results in a timely manner that will impact patient care, most
outpatient clinics and physicians’ ofﬁces rely on RADT assays for
diagnosis of inﬂuenza virus. In fact, even larger hospitals (with on-
site laboratories capable of high volume molecular testing) opt for
these assays because they can ease the patients’ ﬂow especially
with the high patients’ volume during the respiratory season and
results are available while the patient waits. The current available
rapid tests are not optimal as they are not sufﬁciently sensitive. It
seems that the ideal inﬂuenza diagnostic test should combine the
sensitivity provided by a molecular assay with the speciﬁcity and
rapid turnaround time available with RADT assays. In the current
multi-center evaluation study, we evaluated the performance of
AlereTM i Inﬂuenza A&B nucleic acid ampliﬁcation test with test-
ing time of less than 15min, comparable to any rapid test currently
available.
Our results show that the sensitivity and speciﬁcity obtained by
the new rapid technique rivals most real-time RT-PCR techniques.
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Table 1
Performance of the AlereTM i Inﬂuenza A&B nucleic acid ampliﬁcation test for detection of inﬂuenza A and B in comparison with viral cell culture.
AlereTM i Inﬂuenza A&B Inﬂuenza type TP FP TN FN Total % Sensitivity (95% CI) % Speciﬁcity (95% CI) PPV (95% CI) NPV (95% CI)
vs. culture Flu A 90 63 376 2 531 97.8 (91.6–99.6) 85.6 (81.9–88.7) 58.8 (50.5–66.6) 99.4 (97.8–99.9)
Flu B 67 17 437 6 527 91.8 (82.4–96.6) 96.3 (93.9–97.7) 79.8 (69.3–87.4) 98.6 (96.9–99.4)
Table 2
Detection of inﬂuenza A and B by the AlereTM i Inﬂuenza A&B assay in comparison with viral culture after discrepant analysis with the real-time RT-PCR.
n Test sensitivity Test speciﬁcity Prevalence
TP FN % Sens 95% CI TN FP % Spec 95% CI
Flu A
Overall 529 145 1 99.3% 95.6%, 99.9% 376 7 98.1% 96.1%, 99.1% 27.4%
Site 001A 46 6 0 100% 61.0%, 100% 40 0 100% 91.2%, 100% 13.04%
Site 002A 57 11 0 100% 74.1%, 100% 45 1 97.8% 88.7%, 99.6% 19.30%
Site 008A 59 18 0 100% 82.4%, 100% 39 2 95.1% 83.9%, 98.7% 30.50%
Site 009A 294 106 1 99.06% 94.2%, 99.9% 184 3 98.4% 95%, 99.6% 36.39%
Site 010A 33 0 0 N/A N/A 32 1 97.0% 84.7%, 99.5% 0%
Site 011A 15 1 0 100% 20.7%, 100% 14 0 100% 78.5%, 100% 6.67%
Site 012A 25 3 0 100% 31%, 100% 22 0 100% 82%, 100% 12%
Flu B
Overall 526 83 2 97.6% 90.9%, 99.5% 441 0 100% 98.9%, 100.0% 15.77%
Site 001A 46 2 0 100% 34.2%, 100% 44 0 100% 92.0%, 100% 4.34%
Site 002A 57 11 0 100% 74.1%, 100% 46 0 100% 92.3%, 100% 19.30%
Site 008A 59 9 0 100% 70.1%, 100% 50 0 100% 92.9%, 100% 15.25%
Site 009A 292 44 2 95.7% 84%, 99% 246 0 100% 98%, 100% 15.75%
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n addition, all measured values for detection of both inﬂuenza
and inﬂuenza B were similar in children and adults. This is of
articular importance as both the Centers for Disease Control and
revention and the World Health Organization indicate that sen-
itivity of rapid antigen tests for inﬂuenza detection in adults is
ypically less than that for children due to the fact that children
hed more viruses and for longer time. Smaller facilities that lack
xpensive equipments or skilled personnel for molecular testing
ill beneﬁt from a simple to use (with minimal instruction) assay.
he AlereTM i Inﬂuenza A&B nucleic acid ampliﬁcation test is self-
ontained instrument with color-coded consumables and easy to
ollow on-screen instructions that prompt the user (Fig. 2). The
ssay involves on-board lysis of specimen, which does not require
n additional nucleic acid extraction step, contributing substan-
ially to the ease and speed of use. It is important to note that
he testing in this trial was conducted solely by non-laboratorian
nrollers who had receivedminimal training at the initiation of the
tudy. There were only 11 invalid results for inﬂuenza A and 15
or inﬂuenza B, resulting in invalid rates of 2% (11/531) and 2.8%
15/527), respectively; supporting the claim of ease of use of the
ssay.
Loop-mediated isothermal ampliﬁcation assay (LAMP) is
nother DNA ampliﬁcation assay designed for isothermal con-
itions. A recent review cites performances of several reverse
ranscription LAMP assays developed to detect emerging highly
athogenic avian inﬂuenza viruses [25]. A LAMP assay combined
able 3
etection of inﬂuenza A and B in children and adults by AlereTM i Inﬂuenza A&B nucleic ac
eal-time RT-PCR.
Specimen detection TP FP TN FN Total % Sensitivity
Flu A
Children 128 5 320 1 454 99.2 (95.1–9
Adults 17 2 56 0 75 100 (77.0–100
Flu B
Children 70 0 379 2 451 97.2 (89.4–9
Adults 13 0 62 0 75 100 (71.6–10023 0 100% 85.7%, 100% 30.30%
12 0 100% 75.8%, 100% 20%
20 0 100% 80%, 100% 16.66%
with a 10min specimen preparation procedure demonstrated a
combined sensitivity and speciﬁcity for detecting inﬂuenza (A and
B) of 97.9% and 100%with result availability in 30min [26]. Another
simple ampliﬁcation based assay (SAMBA) and visual detection
of nucleic acid on test strip displayed sensitivity and speciﬁcity
of 100% and 97.9% for inﬂuenza virus A and 100% and 100% for
inﬂuenza virus B when compared with a lab developed real-time
RT-PCR [27]. The TAT for the SAMBAwas 135minmaking it unsuit-
able for POC testing.
Special considerations must be given to the study procedures
that may have contributed to the results. First, foam-tipped swabs
were used to collect specimens from the external nares. At present,
the gold standard for respiratory specimen collection is a nasopha-
ryngeal (NP) swab [28], though mid-turbinate (MT) ﬂocked swabs
are becoming increasingly popular and exhibit good performance
[29,30]. Although few studies have demonstrated that nasal swabs
have adequate sensitivity for detection of both inﬂuenza and respi-
ratory syncytial virus compared with nasopharyngeal aspirates or
washes (NPA/W), [31,32] it is possible that nasal swabs collect less
viral secretions compared to latter collection methods. Interest-
ingly, a recent study demonstrates that foam swabs performed
better than nylon ﬂocked swabs for collection of secretions from
the anterior nares for detection of Flu A and B by RADT and PCR
assays [33]. Thus, further studies are needed to investigate the
performance of the AlereTM i Inﬂuenza A&B assay with more com-
monly used NP swabs, MT swabs and NPA/W specimens to provide
id ampliﬁcation test in comparison with viral culture after discrepant analysis with
(95% CI) % Speciﬁcity (95% CI) PPV (95% CI) NPV (95% CI)
9.9) 98.4 (96.2–99.4) 96.2 (91.0–98.6) 99.6 (98.0–99.9)
) 96.5 (87.0–99.4) 89.4 (65.4–98.1) 100 (92.0–100)
9.5) 100 (98.7–100) 100 (93.5–100) 99.5 (97.9–99.9)
) 100 (92.7–100) 100 (71.6–100) 100 (92.7–100)
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dditional data. Second, as the AlereTM i Inﬂuenza A&B nucleic acid
mpliﬁcation test is a truemolecular-based assay, comparisonwith
eal-time RT-PCRmay be desirable. However, the initial aim of this
tudy was to evaluate the AlereTM i Inﬂuenza A&B nucleic acid
mpliﬁcation test in a POC setting similar to RADT assays that have
hosen a viral culture as a reference method. Third, in the current
onﬁguration the device performs one test at a time which may
imit its efﬁciency in high volume situations. This is different from
ost real-time RT-PCR based assays, which typically have higher
hroughput. However, for clinics without such equipment and the
echnical expertise to go along with it, the AlereTM i Inﬂuenza
&B assay would have obvious beneﬁts. Also, the footprint of the
lereTM i Inﬂuenza A&B instrument is small and additional instru-
entation can improve throughput.
In conclusion, the AlereTM i Inﬂuenza A&B nucleic acid ampliﬁ-
ation test demonstrated excellent sensitivity (>99% for inﬂuenza
and >97% for inﬂuenza B across all sites) and speciﬁcity (>95%
or inﬂuenza A and 100% for inﬂuenza B across all sites) for the
etection of inﬂuenza viruses in respiratory specimens. The assay
erformedwell in both children and adult populations seen at hos-
itals and outpatient clinics. The assay is easy to use and provides
esults rapidly. It requires little training and can be performed by
on-laboratory trained POC personnel. These assets suggest that it
epresents the future of rapid testing techniques for detection of
espiratory infections.
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